Structure Therapeutics Inc

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in South San Francisco, CA.

SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21, 2024, in London, UK.

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290  over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study  to evaluate even higher doses of GSBR-1290 over 36 weeks;  first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the first patients have been dosed in the randomized, double-blind, placebo-controlled Phase 2b ACCESS clinical study evaluating GSBR-1290 in participants living with obesity, or overweight with a weight-related comorbidity.

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Natera

Rush Enterprises

GPCR, RUSHA and NTRA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 23, 2024.

Best Momentum Stocks to Buy for October 23rd

Positive 12-week data from phase 2a study of GSBR-1290 targeting obesity patients; significant placebo adjusted mean weight loss of 6.2% & 6.9% achieved for capsule and tablet respectively. One analyst believes that the market for obesity treatments could expand to $200 billion by 2031. The 36-week phase 2b study, using GSBR-1290 for the treatment of patients with obesity, expected to start in Q4 of 2024.

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

The consensus price target hints at an 115.8% upside potential for Structure Therapeutics Inc. Sponsored ADR (GPCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?

SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure's oral small molecule GLP-1 agonist that is planned to enter Phase 2b clinical development for obesity in the fourth quarter of 2024. In addition, Ashley Hall, J.D., has been appointed to the newly created position of Chief Development Officer, and will be responsible for clinical development operations, project management, regulatory affairs and quality assurance.

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Altimmune

Eli Lilly

Novo Nordisk

Viking Therapeutics

Karl-Hendrik Tittel / Getty Images There's also Altimmune (NASDAQ:ALT), whose pemvidutide treatment led to weight loss while preserving lean mass.

Five Top Obesity Stocks to Buy and Hold Long Term

Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced management will participate at the following investor conferences in September:

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Amgen

Corbus Pharmaceuticals Holdings

Scholar Rock Holding Corp

While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the lucrative market, Jefferies analysts said in a research note Monday.

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

GLP-1 agonist drugs like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide are set to become all-time best-selling drugs. Structure Therapeutics has entered the race with an oral GLP-1 candidate, GSBR-1290, showing promising weight loss results and a strong safety profile. Despite competition in the field, Structure's progress and diverse pipeline of candidates make it a potentially strong investment opportunity.

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Look at Eli Lilly (NYSE: LLY ), for example.

3 Promising Biotech Stocks for the Long-Term: August 2024

Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.

What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?

Eli Lilly is having great success in the market for weight loss treatments. Viking is working on a candidate that could potentially outperform Eli Lilly's.

Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.

Zura Bio Ltd

There's always a strong case for undervalued biotech stocks. For one, the industry is only expected to grow.

The 3 Most Undervalued Biotech Stocks to Buy in July 2024

With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs. Just look at Eli Lilly (NYSE: LLY ).

The 3 Smartest Biotech Stocks to Buy With $5K Right Now

Structure Therapeutics is developing a potentially powerful weight loss medicine. That medicine may end up being more effective than Novo Nordisk's offerings.

Could Structure Therapeutics Become the Next Novo Nordisk?

Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.

Structure Therapeutics (GPCR) Rallying on Obesity Drug Data

Structure Therapeutics is a clinical-stage biotech developing a small-molecule drug that mimics an important gut hormone. Early results for Structure Therapeutics' lead candidate compare well with Wegovy and experimental weight management treatments.

Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?

Structure Therapeutics published some strong data from its weight-loss program. Its candidate preliminarily appears to be more effective than the market leader.

Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?

SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the closing of its previously announced upsized underwritten public offering of 10,427,017 American depositary shares (ADSs), each representing three ordinary shares, including the full exercise of the underwriters' option to purchase up to 1,360,045 additional ADSs,  at a public offering price of $52.50 per ADS. The aggregate gross proceeds to Structure Therapeutics from the offering were approximately $547.4 million, before deducting underwriting discounts and commissions and offering expenses. All of the ADSs were offered by Structure Therapeutics.

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the pricing of its upsized underwritten public offering of 9,066,972 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of $52.50 per ADS. The aggregate gross proceeds to Structure Therapeutics from the offering are expected to be approximately $476.0 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Structure Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,360,045 ADSs at the public offering price, less underwriting discounts and commissions. The offering is expected to close on June 7, 2024, subject to the satisfaction of customary closing conditions.

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

SPDR S&P Biotech ETF

Undervalued biotech stocks can offer some of the most explosive opportunities. That is, if you can spot the right one at the right time.

The 3 Most Undervalued Biotech Stocks to Buy in June 2024

SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 8,000,000 American depositary shares (ADSs), each representing three ordinary shares. Structure Therapeutics may offer and sell to certain investors that so choose pre-funded warrants to purchase ordinary shares, represented by ADSs, in lieu of ADSs, in the underwritten public offering. The purchase price of each pre-funded warrant will equal the price per ADS at which the ADSs are being sold to the public in this offering, minus $0.0001, which will be the per share exercise price of each pre-funded warrant. In addition, Structure Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 ADSs at the public offering price, less the underwriting discounts and commissions. The public offering price has not yet been determined. The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Structure Therapeutics (NASDAQ: GPCR ) stock is surging today, up 60% after the biotech company reported promising results of its mid-stage trials for its weight loss pills. Indeed, after 12 weeks, patients on the treatment lost an average of 6.2% of their weight, with one-third of patients losing more than 10% of their weight.

News for Structure Therapeutics Inc Stock (GPCR)